Atea Pharmaceuticals AVIR 深 滬
等待開盤 07-18 09:30:00 美东时间
3.46
-0.030
-0.86%
華盛通- 最 高3.525
- 今 開3.48
- 成交量 38.80万股
- 最 低 3.43
- 昨 收 3.49
- 總市值 2.96亿
- 52周最高 4.145
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 2.455
- 委 比 28.42%
- 總股本 8557.95万
- 歷史最高 94.174
- 量 比 0.96
- 振 幅 2.72%
- 歷史最低 2.455
- 每 手 1
- 風險率 0.38%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Atea Begins Global Late-Stage Trial of Oral Hepatitis C Drug Combo Aimed at Easier, Faster Cure
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced
06-24 19:07
Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing of First Patient in C-FORWARD Outside North America
Atea Pharmaceuticals has initiated the Phase 3 C-FORWARD trial to evaluate a new HCV treatment regimen of bemnifosbuvir and ruzasvir. This trial follows the C-BEYOND trial, both aiming to compare the regimen with the existing sofosbuvir and velpatasvir combination. The new regimen offers a shorter treatment duration, reduced risk of drug interactions, and convenience with no food restrictions. Globally, HCV affects 50 million people, including up...
06-24 11:00
Atea Pharma Presents Results From Full Cohort Of Patients Enrolled In Phase 2 Study Evaluating Once-daily Combination Of BEM And RZR For Treatment Of Hepatitis C Virus
Full Results from Phase 2 Study Confirmed 98% Sustained Virologic Response at 12 Weeks Post-Treatment (SVR12) After Short 8-Week Treatment Duration for RegimenResults from Phase 1 Study Showed Low Risk for Drug-Drug
05-07 19:04
“HPV男女共防计划”北半马主题活动在京举办
澎湃新闻记者 劳理 4月18日，由新华网发起、默沙东（默沙东是美国新泽西州罗威市默克公司的公司商号）支持的“畅跑马拉松，防护你我他”——“HPV男女共防计划...
04-21 22:07
Atea Pharmaceuticals Announces Board Changes and Share Buyback
An announcement from Atea Pharmaceuticals ( ($AVIR) ) is now available. On Apri...
04-17 20:27
Atea Pharmaceuticals announces share repurchase program
Atea Pharmaceuticals (NASDAQ:AVIR) announced on Thursday the appointment of Howard H. Berman to its board. Atea also announced that its board has authorized, and will promptly begin executing upon, t...
04-17 20:07
美股大行评级 | 潜在涨幅223.78%！内克塔治疗获杰富瑞升目标价至2美元，上调至"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1117736711687032832.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 杰富瑞：上调内克塔治疗(NKTR)评级至"买入"，目标价从1美元升至2美元</p> <p>• Roth MKM：维持Lovesac Co.(LOVE)"买入"评级，目标价从22美元升至28美元</p> <p>• Macq
04-14 07:05
Morgan Stanley Maintains Equal-Weight on Atea Pharmaceuticals, Lowers Price Target to $6
Morgan Stanley analyst Matthew Harrison maintains Atea Pharmaceuticals (NASDAQ:AVIR) with a Equal-Weight and lowers the price target from $6.2 to $6.
04-11 23:28
Atea Pharmaceuticals cuts workforce by ~25% in Q1
Atea Pharmaceuticals (NASDAQ:AVIR) announced on Wednesday an about 25% reduction in the workforce during the first quarter. The layoffs are expected to result in cost savings of ~$15M through 2027. Sh...
03-27 02:09
Atea Pharmaceuticals’ Promising Earnings Call Highlights
Atea Pharmaceuticals, Inc. (($AVIR)) has held its Q4 earnings call. Read on for...
03-08 08:10
